Jendoubi F, et al. - Researchers assessed whether omalizumab affords an efficacious as well as safe treatment option for mast cell mediator‐related symptoms among adult patients with mastocytosis. They found one multi‐centre retrospective cohort investigation with 39 patients, one retrospective cohort study with 13 patients, 4 case series and 10 case reports. Overall 69 patients, including 13 patients with cutaneous mastocytosis and 56 with systemic mastocytosis, were analyzed, with mean age 48 years. For the majority of patients, 300 mg was the omalizumab maintenance dose. The mean duration of treatment was 17 months. In 84% of the patients, idiopathic anaphylaxis episodes were completely resolved. At a rate of 43%, 29%, 27%, 11%, 9% and 0%, complete resolution of palpitations, gastrointestinal, cutaneous, neuropsychiatric, respiratory and musculoskeletal symptoms was noted, respectively. Overall, some life‐threatening reactions related to mastocytosis seemed to be prevented with omalizumab treatment. It was inferred that omalizumab may afford a good choice to treat the associated symptoms. However, the evidence relied upon was observational, uncontrolled and from a small number of patients.